Vreni Schoenenberger

Managing Director, External Affairs

2024 - Current

Strategic Advisory Board Member

2023

Advisor

2023

Expert in Residence

2023

Serve as expert advisor for Imperial College London affiliated ventures on topics related to health tech, biotech, clean tech, including: commercialization/go-to-market, pharma partnering, healthcare systems, and value propositions.

Healthtrack Sponsor and Mentor

2022

Advisor

2022

Board Advisor

2022

Global Head, External Affairs and Partnerships (Commercial Development and Market Access)

2021 - 2024

Lead early market shaping, external affairs, and healthcare systems partnerships for all Therapeutic Areas within $8 billion neuroscience portfolio. Member of Franchise Leadership Team and leadership teams for Multiple Sclerosis; Huntington's Disease, Parkinson's, ALS, neuropsychiatry, and neurodegeneration. - Design and execute strategies for faster, broader, and more consistent access to Novartis's neurology treatments, focused on blockbuster launches (Kesimpta) and early pipeline. - Spearhead early market shaping for rare disease and neurodegeneration assets that demand healthcare paradigm shifts to improve access, e.g. novel genetic screening; under-diagnosis; infrastructure build-outs - Build sustainable partnerships with global institutions, political bodies, trade groups, and major patient advocacy, policy, and medical societies to help ensure timely patient access to care and treatment, and future investment in brain health [EU Commission/Parliament, US policy fora; WEF-Davos, WHO/UN, OECD, EFPIA/EUCOPE/PhRMA/IFPMA/BIO; patient advocacy and policy groups.] Board member of European Brain Council and OneNeurology Network. - Foment innovative partnerships and research initiatives to improve health outcomes; address disparities; and improve system efficiency and investment, e.g. with tech and venture sector, universities, civil society, and via public-private partnerships

Global Executive Director, Global Head Of Public Affairs, Neuroscience

2017 - 2021

As member of the Franchise Leadership Team: Lead global public affairs for $8 billion USD neuroscience portfolio, with one of the strongest product pipelines in the industry. Design and implement global and regional government affairs and advocacy strategies for neurological conditions including migraine, MS, and Alzheimer's disease. Support local government affairs implementation across three current launches (Aimovig, Mayzent, Kesimpta) in ~31 countries. - Included the launch of the inaugural Novartis Innovation Prize on accessible tech for people living with neurological coniditions, backed by Sequoia, Wired, Microsoft, Airbnb and Selma Blair and SxSW

Global Head of Strategy & Operations (Sandoz)

2016 - 2017

Drive strategy across Global Compliance function, covering generics, biosimilars and OTCs for 135 markets. Lead cross-divisional policy construction, proactively position Sandoz in relation to the external regulatory/policy landscape, and ensure proper risk mitigation and functional alignment across all markets.

Venture Scout

2021 - 2024

Providing deal flow focused on underrepresented founders/markets.

Mentor

2020 - 2024

One of Europe's premier startup accelerators, focused on medtech, digital health, omics, diagnostics and biomarker and drug discovery platforms.. Mentees include Nostos Genomics, ILoF, Albus Health, Hypervision Surgical, LiliumX Therapeutics; and Mable.